National Institutes of Health, a Component of the US Dept. of Health & Human Services

Other

Blazevic, Vesna

Vesikari, Timo

Timo Vesikari

Robert M Chanock

Albert Z Kapikian

Brian R Murphy

Yasutaka Hoshino

Vesna Blazevic

Kirsi Nurminen

Leena Huhti

Suvi Lappalainen

Eeva Jokela

Lone Simonsen

David M Morens

John R La Montagne

Mary Elaine La Montagne, Legal Representative

Albert Kapikian

The present invention relates to a combined norovirus and rotavirus vaccine for prevention of norovirus and rotavirus infection and/or viral-induced diarrheal and vomiting diseases in man. More specifically, the invention comprises a method of preparing combination vaccine compositions comprising norovirus and rotavirus antigens, in particular mixtures of norovirus VLPs and rotavirus recombinant VP6 protein or double-layered VP2/VP6 VLPs. In addition, the invention relates to methods of inducing an immune response.

Norovirus capsid and rotavirus VP6 protein for use as combined vaccine

The present invention provides vaccine compositions for protection against human rotaviral disease designed for use in particular areas of the world. Human&#xd7; bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined with other VP7 serotypes typically found in the area of interest into a multivalent formulation which provides a high degree of infectivity and immunogenicity. Methods and an administration protocol for producing an immunogenic response without producing an increased risk of intussusception are also provided.

Hexavalent bovine rotavirus reassortant composition designed for use in developing countries

The present invention provides compositions for making a medicament and methods for the administration of a vaccine compositions for protection against human rotaviral disease without significant reactogenicity. Human x rhesus reassortant rotavirus compositions were made which when administered during the first 7 to about 10 days of life, provided a composition which was non-reactogenic followed by booster immunizations at 16 to 18 weeks or 14 to 20 weeks, up to 1 year of age. The immune response induced by the initial neonatal administration of the live rotavirus vaccine composition protects the infant from the reactogenicity of the composition when administered as a second vaccine dose at or after 2 months of age. Administration of the immunogenic composition also is expected to ablate or significantly diminish the increase in the excess of intussusception observed 3 to 7 days following administration of the initial dose of rotavirus vaccine at about 2 to 4 months.

Compositions and method for preventing reactogenicity associated with administration of immunogenic live rotavirus compositions

Growing community of inventors

Tampere, Finland

Timo Vesikari